Company Overview
Snapshot
Founded in January 2014 by Kobi Segev and Osnat Attal-Damon, Cellosign operates with 11–50 employees. The company focuses on enhancing business processes for call centers. In October 2021, CellOrigin, a related entity, secured a new investment round to advance its iPSC-CAR-Macrophage technology platform.
Business overview
Cellosign develops an application designed to streamline business processing between customer service representatives and customers. Its core technology enables interactive document sharing through real-time, bi-directional viewing and annotation of data, including eSignatures. The company serves call centers, aiming to increase transaction close rates and reduce operational complexity by removing barriers to digital mobile signatures. Cellosign operates within the Business Software sector, specifically targeting Enterprise & Professional Services and Call Centers with its SaaS solutions.
Strategic signal
In October 2021, CellOrigin, a company with a similar name, secured a new investment round for developing its iPSC-CAR-Macrophage technology platform. While this news does not directly pertain to Cellosign's core business of mobile digital signatures for call centers, it indicates activity within a broader ecosystem that could be relevant to investors tracking innovative technology development.
Log in to access full profile ›Company Intelligence Q&A
- When was Cellosign founded?
- Cellosign was founded in January 2014.
- Who are the founders of Cellosign?
- Cellosign was co-founded by Kobi Segev and Osnat Attal-Damon.
- What is Cellosign's primary product?
- Cellosign provides an application that facilitates efficient business processing between customer service representatives and customers, enabling interactive document sharing and eSignatures.
- What markets does Cellosign serve?
- Cellosign serves geomarkets including the United States, Israel, and the United Kingdom, focusing on call centers within the Enterprise & Professional Services sector.
- What was a notable development for a related entity in October 2021?
- In October 2021, CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform.